osteoarthritis
Conditions
Interventions
Patients in the intervention group will be treated with duloxetine 1dd60mg and
usual care during one year. The patients in the control group will be treated
with usual care which consists of analges
Chronic pain
Duloxetine
General practice
Osteoarthritis
Sponsors
Erasmus MC, Universitair Medisch Centrum Rotterdam
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1) having hip or knee OA based on the clinical ACR criteria, and 2) having chronic pain (most days of the last three months) in hip or knee, and 3) either: (i) a contra-indication for NSAIDs; (ii) adverse reactions of NSAIDs; or (iii) insufficient benefit of NSAIDs.
Exclusion criteria
Exclusion criteria: 1) on waiting list for hip/knee replacement, and 2) use of antidepressants, 3) contra-indication of duloxetine (use of Monoamine Oxidase Inhibitors, having uncontrolled narrow-angle glaucoma, in combination with (other) central nervous system acting drugs, in combination with thioridazine, hypersensitivity to duloxetine, disturbed liverfunction, renal insufficiency (creatinine clearance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome of this study will be pain at 3 months measured with the WOMAC pain subscale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes will be pain at one year (WOMAC pain subscale), disability (WOMAC function subscale), adverse reactions, quality of life, compliance to treatment, patients*satisfaction, OARSI-OMERACT, co-interventions, costs (iMCQ, iPCQ). | — |
Countries
The Netherlands
Outcome results
None listed